Cysteinyl leukotrienes (cysLTs), leukotriene C 4 (LTC 4 ), LTD 4 , and LTE 4 are proinflammatory lipid mediators with pathobiologic function in asthma. LTE 4 , the stable cysLT, is a weak agonist for the type 1 and type 2 cysLT receptors (CysLTRs), which constrict airway smooth muscle, but elicits airflow obstruction and pulmonary inflammation in patients with asthma. We recently identified GPR99 as a high-affinity receptor for LTE 4 that mediates cutaneous vascular permeability. Here we demonstrate that a single intranasal exposure to extract from the respiratory pathogen Alternaria alternata elicits profound epithelial cell (EpC) mucin release and submucosal swelling in the nasal mucosa of mice that depends on cysLTs, as it is absent in mice deficient in the terminal enzyme for cysLT biosynthesis, LTC 4 synthase (LTC 4 S). These mucosal changes are associated with mast cell (MC) activation and absent in MC-deficient mice, suggesting a role for MCs in control of EpC function. Of the three CysLTRs, only GPR99-deficient mice are fully protected from EpC mucin release and swelling elicited by Alternaria or by intranasal LTE 4 . GPR99 expression is detected on lung and nasal EpCs, which release mucin to doses of LTE 4 one log lower than that required to elicit submucosal swelling. Finally, mice deficient in MCs, LTC 4 S, or GPR99 have reduced baseline numbers of goblet cells, indicating an additional function in regulating EpC homeostasis. These results demonstrate a novel role for GPR99 among CysLTRs in control of respiratory EpC function and suggest that inhibition of LTE 4 and of GPR99 may have therapeutic benefits in asthma.C ysteinyl leukotrienes (cysLTs), leukotriene C 4 (LTC 4 ), LTD 4 , and LTE 4 are lipid mediators detected during asthma exacerbations triggered by allergen (1), aspirin (2, 3), and respiratory viruses (4). The cysLTs elicit vascular permeability, inflammation, and bronchoconstriction through three G-protein-coupled receptors. The type 1 cysLT receptor (CysLTR), CysLT 1 R, is the highaffinity receptor for LTD 4 and the dominant CysLTR mediating airway smooth muscle constriction (5-8). The type 2 CysLTR, CysLT 2 R, has prominent effects on the vascular endothelium (9-12) and also elicits bronchial constriction (13,14). LTE 4 , the stable cysLT (15-18), is a weak agonist for CysLT 1 R and CysLT 2 R in transfected cells (5, 19), but elicits airflow obstruction in patients with asthma (20-22). Moreover, LTE 4 has comparable activity to LTC 4 and LTD 4 in eliciting a wheal and flare response in human skin (23), and LTE 4 elicits cutaneous vascular permeability in mice lacking both CysLT 1 R and CysLT 2 R, suggesting the existence of a high-affinity receptor for LTE 4 , which was recently identified as GPR99 (24,25). However, the mechanism by which LTE 4 induces lung pathobiology and the role of GPR99 remain poorly understood.The cysLTs are derived from arachidonate through the serial enzymatic actions of 5-lipoxygenase and leukotriene C 4 synthase (LTC 4 S). LTC 4 , the terminal product of intrac...